Literature DB >> 6144347

Neuroleptic malignant syndrome.

E Szabadi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6144347      PMCID： PMC1441030          DOI： 10.1136/bmj.288.6428.1399-a

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  17 in total

1.  [A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses].

Authors:  J DELAY; P PICHOT; T LEMPERIERE; B ELISSALDE; F PEIGNE
Journal:  Ann Med Psychol (Paris)       Date:  1960-01       Impact factor: 0.380

2.  Catatonia and malignant syndrome: a possible complication of neuroleptic administration. Report of a case involving haloperidol.

Authors:  D R Weinberger; M J Kelly
Journal:  J Nerv Ment Dis       Date:  1977-10       Impact factor: 2.254

3.  Lithium carbonate, haloperidol, and irreversible brain damage.

Authors:  W J Cohen; N H Cohen
Journal:  JAMA       Date:  1974-12-02       Impact factor: 56.272

4.  Rigidity, hyperpyrexia and coma following fluphenazine enanthate.

Authors:  H Y Meltzer
Journal:  Psychopharmacologia       Date:  1973

5.  [Pharmacology of catatonigenic agents. 5. The effect of neuroleptics].

Authors:  G Stille
Journal:  Arzneimittelforschung       Date:  1971-06

6.  [Malignant syndromes and sudden death, during treatments with simple and delayed-action neuroleptic drugs].

Authors:  M Bourgeois; J Tignol; P Henry
Journal:  Ann Med Psychol (Paris)       Date:  1971-12       Impact factor: 0.380

Review 7.  The pathophysiology of extrapyramidal side-effects of neuroleptic drugs.

Authors:  C D Marsden; P Jenner
Journal:  Psychol Med       Date:  1980-02       Impact factor: 7.723

8.  Malignant neuroleptic syndrome--its present status in Japan and clinical problems.

Authors:  H Itoh; N Ohtsuka; K Ogita; G Yagi; S Miura; Y Koga
Journal:  Folia Psychiatr Neurol Jpn       Date:  1977

9.  The neuroleptic malignant syndrome.

Authors:  S N Caroff
Journal:  J Clin Psychiatry       Date:  1980-03       Impact factor: 4.384

10.  Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors.

Authors:  P R Sanberg
Journal:  Nature       Date:  1980-04-03       Impact factor: 49.962
View more
  7 in total

Review 1.  Clinical features, pathogenesis and management of drug-induced rhabdomyolysis.

Authors:  C Köppel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

2.  Neuroleptic malignant syndrome successfully treated with amantidine.

Authors:  J Woo; R Teoh; J Vallance-Owen
Journal:  Postgrad Med J       Date:  1986-08       Impact factor: 2.401

3.  Neuroleptic malignant syndrome: another medical cause of acute abdomen.

Authors:  T C Lo; M R Unwin; I W Dymock
Journal:  Postgrad Med J       Date:  1989-09       Impact factor: 2.401

4.  Neuroleptic malignant syndrome: a case for electroconvulsive therapy.

Authors:  C C Harland; M M O'Leary; R Winters; J Owens; B Hayes; V Melikian
Journal:  Postgrad Med J       Date:  1990-01       Impact factor: 2.401

Review 5.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

Review 6.  The hypothalamus in Parkinson disease.

Authors:  R Sandyk; R P Iacono; C R Bamford
Journal:  Ital J Neurol Sci       Date:  1987-06

7.  Neuroleptic malignant syndrome: a diagnostic dilemma.

Authors:  S M Sagar
Journal:  J R Soc Med       Date:  1991-08       Impact factor: 18.000
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.